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OBJECTIVES: Clinical trials of oncology products often allow crossover of control
patients to the treatment arm following disease progression. This can underesti-
mate a product’s overall survival (OS) and raises challenges for cost-effectiveness
analyses compared.METHODS: A lifetime model compared the cost-effectiveness
of a hypothetical pancreatic cancer therapy (CRG001) to gemcitabine. Gemcitabine
survival data were derived from published studies. A hazard ratio of 0.55 was
assumed for CRG001. CRG001 cost $2500 every 2 weeks for a maximum of 12 cycles
and gemcitabine cost $200 every 1week for amaximumof 24 cycles. Analyseswere
conducted: 1) 0%; 2) 50%; and 3) 85% crossover of gemcitabine patients to CRG001.
Patient crossover occurred at the time of disease progression. Crossover patients
received the CRG001 hazard ratio. Patients progressing in CRG001were assumed to
receive palliative care. A secondary analysis allowed 50% crossover but excluded
second-line costs of CRG001. Costs and outcomeswere discounted at 5%. RESULTS:
The cost per QALY gained for CRG001 comparedwith current carewas $81,352with
no cross-over, $69,292 with 50% crossover and 40,992 with 85% crossover. In the
analysiswhere the cost of CRG001was excluded in crossover patients, the ratiowas
$140,118. CONCLUSIONS: The first three analyses illustrate that CRG001 cost-ef-
fectiveness decreases with increasing cross-over of gemcitabine patients, if the
costs of CRG001 for crossover patients are included. In our experience, however,
reimbursement agencies often require a primary analysis that excludes second-
line costs of the study drug for patients that cross-over. This analysis yields a high
ratio that could lead to a negative reimbursement decision. In this case, where
second-line CRG001 costs are excluded, adjustment of OS for crossover of gemcit-
abine patients is required. Overall, consideration must be given to the extent and
potential impact of crossover when conducting cost-effectiveness analysis of new
oncology products.
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OBJECTIVES: To quantify patients’ benefit-risk preferences for benefits, toxicities,
and serious adverse events of advanced RCC treatments. METHODS: Adult resi-
dents in the United States, with a self-reported diagnosis of RCC completed a
web-enabled choice-format conjoint survey consisting of a series of 10 treatment-
choice questions, and a pair of hypothetical RCC medication profiles. Each profile
had different attributes, i.e., efficacy [PFS], tolerability [fatigue, stomach problems,
mouth sores, hand-foot syndrome (HFS)], serious adverse events (lung damage and
liver failure), andmode of administration. Treatment-choice questions were based
on a predetermined experimental design with known statistical properties. Ran-
dom-parameters logit was used to estimate relative preference weights for each
attribute level, mean relative importance weights; and calculate risk tolerance for
each adverse event for different improvements in PFS. RESULTS: A total of 272
respondents completed the survey. A 7-month improvement in PFS was the most
important attribute. Remaining attributes were ranked in decreasing order of im-
portance: eliminating severe fatigue (7.0; 95% CI: 4.6-9.4), eliminating severe stom-
ach problems (7.0; 95% CI: 4.7-9.3), eliminating a 2% liver-failure risk (6.1; 95% CI:
4.0-8.2), eliminating severe mouth sores (5.7; 95% CI: 3.7-7.7), eliminating severe
HFS (4.5; 95% CI: 2.7-6.4), eliminating a 2% lung-damage risk (4.1; 95% CI: 2.5-5.8),
and switching from infusion once aweek to 1 pill once a day (2.5; 95%CI: 1.4-3.6). To
increase PFS by 1 month (baseline: 3 - 4 months), patients accepted a maximum
level of lung damage risk of 1.0% (95% CI: 0.8% - 1.4%) and liver failure risk of 0.7%
(95% CI: 0.4% - 1.0%). A 7-month improvement in PFS was 2 times as important as
eliminating severe HFS and a 2.0% risk of lung damage (P  0.05). CONCLUSIONS:
PFS was the most important outcome for RCC patients while severe fatigue and
severe stomach problems were rated as the most troublesome toxicities.
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OBJECTIVES: To develop and validate a patient-reported questionnaire to assess
the quality of life (QOL) outcomes of Indian breast cancer (BC) patients.METHODS:
A 27-item questionnaire was developed by literature review, patient interviews
(n6) and expert opinions (n15). The 24-item questionnaire was finalized. Total
11 domains were considered. The questionnaire was translated to local languages
and then it was administered to BC patients (n30) irrespective staging of cancer
and type of therapy. The patients were interviewed and the responses were ob-
tained. Internal consistency, acceptability, content validity, test-retest reliability of
the questionnaire was determined and assessment the scores was performed
statistically. RESULTS: A 24-item questionnaire was developed as per literature
review, patient interviews and expert opinions. Cronbach’s alpha value for the
questionnaire was 0.93. Patients understood the questionnaire and found the
items to be relevant indicating content validity. The statistical assessment of the
scores was not showing the association between scores with age or stage of BC as
sample size was less. CONCLUSIONS: The questionnaire shows good internal con-
sistency, acceptability, content validity and test-retest reliability. It can be used to
determine the QOL of BC patients. To our knowledge there is no other question-
naire to determine the QOL outcomes of Indian BC patients. For better results the
instrument is needed to be used in larger population.
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OBJECTIVES: Translation of patient reported outcomes (PRO) measures is an es-
sential component of the researchmethodology required when preparing for mul-
tinational clinical trials. One suchmeasure is the Functional Assessment of Cancer
Therapy-Thrombocytopenia 18 questionnaire (FACT-Th18), which evaluates the
quality of life (QOL) of cancer patients with thrombocytopenia. METHODS: This
study set out to linguistically validate the FACT-Th18 scale for use in China, Greece,
HongKong, Japan, India, Israel, Korea, Taiwan andThailand. The combined sample
consisted of 160 patients (81males/79 females) diagnosed with thrombocytopenia.
Patientmean agewas 46 years, and at the time of administration, 146 patientswere
receiving treatment. The sample consisted of patients who speak Arabic, Chinese-
Traditional, Chinese-Simplified, Greek, Gujarati, Hebrew, Hindi, Japanese, Kan-
nada, Korean, Malayalam, Marathi, Punjabi, Tamil, Telugu and Thai. The FACT-
Th18 was translated based on the established FACIT methodology. Patients
completed the respective translated questionnaire corresponding to their primary
language and then participated in a cognitive interview to determine if there were
any problems with the translations or item content. Quantitative analyses were
performed on the combined sample and participant comments were analyzed
qualitatively in order to confirm the validity of the translations. RESULTS: During
the translation process terms such as “petechiae”, “pinpoint bruising” and “platelet
transfusions” proved difficult to translate. The FACT-Th18 translations proved rel-
evant to patients from a wide range of countries and were well understood. Very
few items required adjustment to translations as a result of pilot-testing.
CONCLUSIONS: The FACT-Th18 demonstrated linguistic validity across all 16 lan-
guages. The translations are considered acceptable for PRO assessment in interna-
tional research and clinical trials.
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OBJECTIVES: Estimating prevalence rates for raremedical conditions such as renal
cell carcinoma (RCC) at state level by age and sex is difficult due to the paucity of
available data resources. Available information may be fragmented because of a
lack of national level surveillance. The use of commercialmedical claim data alone
is insufficient for estimation because the use of these data tends to result in biased
estimates due to business practices of managed care organization. METHODS:
Invision Data Mart and the US census data were used to address this problem. The
study inclusion criteria for defining RCC patients was age of 18 years or older
without prior history of HIV/AIDS, HVB, or HVC diagnoses and had at least 2 out-
patient medical claim with an associated ICD9 code of 189.0. First, we estimated
prevalence rates for themedical conditions by state, age, and sex using ICD9 codes
from the commercial data (2002-2010). Then, reanalyzed using post-stratification
weights derived from the 2010 Census data to reflect the state, age, and sex distri-
bution of the US population. RESULTS: The sum of the adjusted state population
weights yielded a total that was similar to the 2010 US census data, and adjusted
values suggest that the overall 2010 US RCC prevalence is approximately 85k. Since
there is no state level prevalence information for RCC by age and sex available, an
indirect comparison was made by comparing the overall prevalence from Kantar
Health (CancerMpact®). The overall prevalence estimates were similar; Kantar
Health: 86,853 versus Study Estimate: 84,712. CONCLUSIONS: This method pro-
duced prevalence rates that take important health care related factors into account
in the estimation process. We recommend the use of this combined approach for
the estimation of prevalence rates of rare disease conditions and procedures.
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OUTCOMES ASSOCIATED WITH SEVERE COMORBIDITIES IN HOSPITALIZED
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OBJECTIVES: To assess economic and clinical characteristics of severe comorbidi-
ties during inpatient hospitalizations in persons with HIV/AIDS. METHODS: The
Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utiliza-
tion Project (H-CUP) Nationwide Inpatient Sample (NIS) was used in this retrospec-
tive database study spanning 2005-2009. Inpatient cases of HIV/AIDS among per-
sons 18 years of age or older were used as inclusion criteria. Key clinical
comorbidities analyzed included organ insufficiency/failure, cancers, heart failure,
pulmonary circulation disorders, coagulopathies, fluid/electrolyte disorders, and
wasting syndromes/weight loss. Outcomes of inpatient mortality and hospital
charges were assessed via multivariate logistic and gamma regression, respec-
tively, after controlling for comorbidities, patient demographics, hospital charac-
teristics, payer, and lengths of stay. RESULTS: There were 1,227,718 overall inpa-
tient cases of HIV/AIDS from 2005-2009 in the United States, averaging 44.8 (10.7)
years of age, 6.7 (9.0) days for length of stay, and inpatient charges of $36,004
(59,303). Mortality occurred in 41,609 cases, constituting 3.4% of all HIV/AIDS
hospitalizations and averaging 47.0 (11.1) years of age, 13.4 (17.4) days for length
of stay, and inpatient charges of $104,558 (136,254). Fluid/electrolyte disorders
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